This article is more than 5 years old. Information may no longer be current.

STAAR receives approval certification to market Visian ICL with CentraFLOW in China

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

STAAR Surgical announced it has received approval certification from the China Food and Drug Administration to market Visian ICL with CentraFLOW technology in China, according to a company press release.

The Visian ICL with CentraFLOW features a proprietary port in the center of the ICL optic that is designed to optimize the flow of fluid in the eye without affecting the patient’s quality of vision. Additionally, use of the CentraFLOW eliminates the need to perform a YAG peripheral iridotomy procedure within days of ICL implantation, according to the release.

This approval, which includes both the myopic ICL and the toric ICL with expanded approval ranges for both myopia and astigmatism, increases the potential number of patients who can be treated with Visian ICL in China, according to the release.

“We now have the opportunity to expand our share and growth in China, which included a 27% ICL revenue growth milestone in the most recent quarter,” Don Todd, president of the Asia-Pacific region of STAAR Surgical, said in the release.